alexa The Quinoline-3-carboxamide Paquinimod Prevents Development Of Diabetes In The Non-obese Diabetic (NOD) Mouse
ISSN: 2155-9899

Journal of Clinical & Cellular Immunology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

8th European Immunology Conference
June 29-July 01, 2017 Madrid, Spain

Sahar Tahvili, Marie Torngren, Dan Holmberg, Tomas Leanderson and Fredrik Ivars
Lund University, Sweden
Personalmatsalen Active Biotech, Sweden
Posters & Accepted Abstracts: J Clin Cell Immunol
DOI: 10.4172/2155-9899-C1-037
The NOD mouse spontaneously developed type 1 diabetes (T1D). At the age of 3-4 weeks, there was detectable infiltration of mononuclear cells in the pancreatic islets of Langerhans of these mice. This process known as insulitis, causes selective cell death of the insulin producing β-cells in the islets. Female NOD mice displayed severe insulitis at about 15 weeks of age and developed hyper-glycaemia at around 15-30 weeks of age. We have previously shown that the immunomodulatory compound paquinimod can reduce the influx of monocytes to sites of inflammation. Since monocyte-derived macrophages are known to be involved in pathogenesis in NOD pancreas, we have in here investigated the impact of paquinimod treatment on the development of T1D in the NOD mouse. In cohorts of mice treated between weeks 10 to 20 of age and followed up until 40 weeks of age, we observed dosedependent reduction of incidence of disease as well as delayed onset of disease. Further, in mice treated with paquinimod from 15 weeks of age, most of the treated mice had not developed glycosuria at 30 weeks of age and displayed strongly reduced insulitis. Importantly, in these treated mice there were significantly more non-infiltrated islets than in untreated controls. Collectively, these data indicate that paquinimod treatment inhibits progression of insulitis to overt diabetes in the NOD mouse.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version